secwatch.observer — SEC 8-K summary
======================================

Issuer:     SERA PROGNOSTICS, INC. (SERA)
CIK:        0001534969
Form:       8-K
Filed at:   2023-03-22T23:59:59+00:00
Accession:  0001534969-23-000028
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sera Prognostics reports Q4 net loss $9.7M, revenue $65k; positive AVERT PRETERM trial results
--------------------------------------------------------------------------------

- Q4 2022 net loss $9.7M vs $12.5M in Q4 2021; revenue $65k vs $26k.
- Full year 2022 revenue $268k; cash and securities $104.0M at Dec 31, 2022.
- AVERT PRETERM trial showed generalizability of PreTRM test-and-treat strategy improving neonatal outcomes.
- PRIME study surpassed required 2,800 subject enrollment; interim look analysis expected by year end.
- R&D expenses $3.5M in Q4; SG&A $6.9M down from $9.5M due to sales streamlining.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534969/000153496923000028/0001534969-23-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534969/000153496923000028/sera-20230322.htm
  HTML page:      https://secwatch.observer/filing/0001534969-23-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer